IVIG Treatment in Systemic Sclerosis
NCT01785056 is an interventional trial sponsored by Georgetown University. As of 21 Nov 2026, it has a status the registry marks as unknown. It studies Immunoglobulin G in Diffuse Scleroderma and Systemic Sclerosis. The registry lists an enrollment of 14 participants at 2 sites in 1 country. The registry lists a start date of 30 Apr 2013 and a primary completion date of 31 Jan 2018.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT01785056 |
| Status | Unknown |
| Study type | Interventional trial |
| Lead sponsor | Georgetown University |
| Enrollment | 14 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Diffuse Scleroderma and Systemic Sclerosis |
| Drugs | Immunoglobulin G |
| Start | 30 Apr 2013 |
| Primary completion | 31 Jan 2018 |
| Study completion | 31 Jan 2019 |
| Last update posted | 17 Jul 2018 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Virginia D Steen, MD
Georgetown University Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Georgetown University Hospital
Washington D.C.
- Johns Hopkins Hospital
Baltimore
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT01785056
Each answer restates registry values shown on this page.
What is NCT01785056?
NCT01785056 is an interventional trial sponsored by Georgetown University. It studies Immunoglobulin G in Diffuse Scleroderma and Systemic Sclerosis.
Who leads NCT01785056?
The registry names Virginia D Steen, MD (principal investigator, Georgetown University Hospital) as the overall official.
Where does NCT01785056 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT01785056 study?
The registered drug and biological interventions are Immunoglobulin G.
When is NCT01785056 expected to complete?
The registry lists a primary completion date of 31 Jan 2018 and a study completion date of 31 Jan 2019. The sponsor last updated the record on 17 Jul 2018.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.